Search

everythinglearnresearchcommunity

for

Search:↓

Serum DHT levels and their variations when using dutasteride for hair loss treatment.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.

The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

After switching from finasteride to dutasteride, the user experienced a 25% increase in total testosterone and a 150% increase in free testosterone, with side effects like brain fog and nipple tingling. The user plans to consult a lab for accuracy and adjust the dutasteride dosage to manage side effects.

DHT is important for sexual function and mood, but finasteride and dutasteride can reduce DHT, causing side effects like reduced libido and erectile dysfunction. These treatments are effective for hair loss, but their impact on DHT leads to debate.

A user shared their experience 36 days after a hair transplant of 5500 grafts in Delhi, using topical minoxidil and finasteride, and plans to start oral finasteride. They reported less shedding than expected and strong early growth, while also maintaining a healthy lifestyle.

OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.

Higher doses of dutasteride reduce scalp DHT more effectively than finasteride, but have diminishing returns after 3mg daily and may cause more side effects. Combining dutasteride with topical minoxidil can enhance results, but using both finasteride and dutasteride together is unnecessary.

The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.

New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports positive results from using topical dutasteride.

Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

A 27-year-old man shared his hormonal panel results after one year of taking finasteride 1mg/day for hair loss, showing his DHT levels nearly doubled. He reported stabilized hair loss with mild side effects that resolved, and he is considering a hair transplant but is concerned about the increased DHT levels and potential treatment options.

Finasteride does not significantly affect muscle gains and can slightly increase testosterone levels. Creatine is generally considered safe to use with finasteride, though some believe it may increase DHT levels, potentially affecting hair loss.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

A user started taking finasteride 1mg/day for hair loss but hasn't seen results yet. They also take vitamins and asked about adding minoxidil and the effectiveness of LLLT.